Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis.
about
Recent developments in treatment of latent tuberculosis infectionDiagnosis and treatment of latent infection with Mycobacterium tuberculosisCost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants.Predictors and prevalence of latent tuberculosis infection in patients receiving long-term hemodialysis and peritoneal dialysis.Tuberculosis, lung infections, and interstitial lung disease in AJRCCM 2000.Adverse reactions to first-line antituberculosis drugs.Risk of Tuberculosis Among Patients on Dialysis: The Predictive Value of Serial Interferon-Gamma Release AssayInflammatory markers and clinical characteristics for predicting persistent positivity of interferon gamma release assay in dialysis populationTreatment of latent tuberculosis infection: An update.Optimizing statin treatment decisions for diabetes patients in the presence of uncertain future adherence.Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.Use of isoniazid for latent tuberculosis infection in a public health clinic.
P2860
Q24630473-9A4AA18D-B24D-407C-8E74-89D4ACE3E854Q27021614-60781DF3-9A7B-49A0-9C66-E96F805D0503Q33247229-56F91907-B7FB-4201-AB2C-CA793943A70EQ34390905-DE667CF0-1D0D-4074-8C6E-8ED38E1103C0Q34457540-8BC2F13B-E92B-440D-AF04-D2EACACEECD3Q34497890-A771E177-8CA4-4C6D-B21C-A7B548311803Q36988815-D342C586-4063-4BA9-9FF1-AFFB35EAE284Q37310597-D3A524AD-D6CF-4F0A-9303-F47EAE0D7FFFQ37735306-1433BCFC-D73D-4EBE-A7EC-47240A779EA3Q39755456-4AB8E5AE-1639-4B85-992B-74DCDF4E085FQ40878500-DE81DEC9-4957-4D29-A13F-8C8B63ACF92AQ42110466-ABF39DCF-B31F-45F5-AD87-6EC9A2307A2FQ44440459-79E8CC12-A252-4814-82F8-2EE03F0B592E
P2860
Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Twelve months of isoniazid com ...... d cost-effectiveness analysis.
@en
Twelve months of isoniazid com ...... d cost-effectiveness analysis.
@nl
type
label
Twelve months of isoniazid com ...... d cost-effectiveness analysis.
@en
Twelve months of isoniazid com ...... d cost-effectiveness analysis.
@nl
prefLabel
Twelve months of isoniazid com ...... d cost-effectiveness analysis.
@en
Twelve months of isoniazid com ...... d cost-effectiveness analysis.
@nl
P2093
P2860
P1476
Twelve months of isoniazid com ...... d cost-effectiveness analysis.
@en
P2093
Antonio Paz E
Cuthbert SS
Hopewell PC
P2860
P304
P356
10.1164/AJRCCM.162.5.2003028
P407
P577
2000-11-01T00:00:00Z